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INTRODUCTION
Patients with chronic obstructive pulmonary disease (COPD) frequently suffer a limitation of their exercise capacity, 1 which is multifactorial and results from complex interactions between physical, both pulmonary and non-pulmonary, and psychological factors. [2] [3] [4] Exercise capacity limitation worsens health status and reduces survival. 5, 6 Furthermore, exercise capacity often declines over time. [7] [8] [9] [10] This decline appears to be independent of longitudinal changes in airflow limitation 9, 10 and it is a strong predictor of mortality. [8] [9] [10] Finally, exercise capacity decline can be prevented with therapeutic strategies including pulmonary rehabilitation. 11 Therefore, it is important to identify what factors are associated with exercise capacity decline in COPD.
To date, only a few studies have investigated risk factors associated with exercise capacity decline in COPD, mainly using the 6-minute walk test (6MWT) as an index of exercise capacity. 7, 12, 13 These studies identified that older age, 4 lower body mass index (BMI), 4 more severe airflow limitation (FEV 1 ) 4, 7, 12 and a lower level of regular physical activity 12 were related to exercise capacity deterioration. However, these previous studies 7, 12, 13 suffered from varying proportions of losses during follow-up, which conditions their results to a certain degree of bias due to selective attrition. 14 Nowadays statistical methods are available to account for missing values during follow-up, thus increasing the accuracy of estimated statistical associations. 15 Moreover, the relationship between lung hyperinflation, a variable contributing to dyspnoea, morbidity and mortality in COPD, [16] [17] [18] and exercise capacity decline has not 8 been reported in any of the of the abovementioned studies. 7, 12, 13 Inspiratory capacity-tototal lung capacity (IC/TLC) ratio, a static hyperinflation-derived variable reflecting the mechanical inspiratory constraint, has been shown to be an important predictor of exercise performance in cross-sectional studies 16, [19] [20] [21] . Therefore, IC/TLC might be a determinant of exercise capacity deterioration in COPD.
We hypothesised that IC/TLC can be a predictor of the decline in exercise capacity in COPD patients and tested this contention in 342 COPD patients prospectively followedup in the "Phenotype and Course of COPD (PAC-COPD)" Study. 22 
METHODS

Study design and participants
Subjects were recruited during their first hospitalisation due to a COPD exacerbation in 9 teaching hospitals in Spain between January 2004 and March 2006. The diagnosis of COPD (post-bronchodilator forced expiratory volume in the first second to forced vital capacity ratio (FEV 1 /FVC) <0.70) was confirmed in stable clinical conditions, at least 3 months after discharge, during a first evaluation visit. 23 Following the original protocol, 18 to 24 months (2006-2008) after this first visit, patients were invited to participate in a second evaluation for follow-up assessment. Of the 342 patients originally recruited into the PAC-COPD study 24 226 (66%) had measures of exercise capacity in the two evaluation visits. Subjects lost to follow-up were older, had more co-morbidities and lower FEV 1, as reported elsewhere. 25 The Clinical Research Ethical Committee of each centre approved the study and written informed consent was obtained from all participants.
Measurements
Exercise capacity was assessed by the 6MWT. 26 In the first visit, patients completed two tests with at least a 30-min rest between them, and the longest of both 6-minute walk distances (6MWD) was used for analysis. Only one test was conducted in the second evaluation. The annual rate of change in exercise capacity was defined as the difference between the distance walked at the second evaluation minus that at baseline divided by follow-up time in each subject. Heart rate, oxygen saturation, dyspnoea and fatigue score (Borg scale) 27 were collected before and at the end of each exercise test.
At baseline, while on stable conditions, patients also underwent complete lung function tests (forced spirometry, plethysmographic lung volumes, diffusing capacity for carbon monoxide (DLco) and arterial blood gases). Static lung hyperinflation was considered as any value of TLC above 120% of predicted. 28 IC/TLC was taken as an index of inspiratory constraint derived from static hyperinflation of the lung. 17 For analysis, disease severity was classified according to the American Thoracic Society and European Respiratory Society (ATS/ERS) criteria. 29 Patients also answered a questionnaire that included socio-demographic data, smoking, 
Statistical analysis
Sample size power estimation is detailed in the Online Supplement.
To account for selective attrition and missing values, we used multiple imputation (20 times) through chained equations. 15 By performing these analyses all data from 342 PAC-COPD patients were included. Characteristics of study participants using complete cases and imputed datasets have been previously reported. 25 IC/TLC, as a continuous variable or categorized in tertiles, was selected a priori as the main exposure variable. The bivariate association between IC/TLC, as well as other potential determinants of exercise capacity decline, and change in 6MWD (dependent variable) were analysed using Students' t test or ANOVA, as appropriate depending on the number of categories of the independent variable. Those of them that were significantly related to the outcome were then introduced in a multiple linear regression model to determine the predictors of exercise capacity decline, after adjusting for baseline 6MWD. Variables were kept in the model if they were significantly associated with the outcome and/or they modified (at least by 10%) the coefficient of other variables in the model. Goodness of fit was assessed by means of normality of residuals, heteroscedasticity, linearity, collinearity and identification of influential data. Because previous research has identified different determinants of exercise capacity in obese and normal weighted COPD patients 31 , we stratified the models according to BMI.
Additional analyses using residual volume/total lung capacity (RV/TLC) as a marker of air trapping were also implemented. Finally, sensitivity analyses were conducted (i) using complete case analyses, (ii) measuring changes in the 6MWD as percentage with respect to baseline level, (iii) excluding patients enrolled in pulmonary rehabilitation programs, and (iv) forcing into the model variables previously reported to be associated with 6MWD decline. 7, 12, 13 Analysis was conducted using Stata 12.1 (StataCorp, College Station, TX, USA). Table 1 shows the main clinical and functional characteristics of the 342 study participants at baseline. Patients were mostly male (92%) with a mean+SD age of 67.9+8.6 years. Airflow limitation was moderate to severe in the majority of patients (mean post-bronchodilator FEV 1 was 54+17% of predicted) but there was significant variability. Static hyperinflation was present in 67 (20%) patients. Thirteen (5%) patients were enrolled in pulmonary rehabilitation programs, 8 (2%) were on continuous long-term oxygen therapy, and 120 (35%) on chronic inhaled steroids. remained statistically significantly associated with the 6MWD decline, after adjusting for baseline 6MWD. The adjusted predicted change in 6MWD (and 95% confidence interval) was plotted against IC/TLC ratio (Figure 2) , and shows that the lower the baseline IC/TLC ratio, the greater the longitudinal decline in exercise capacity in a linear dose-response shape.
RESULTS
Additional analyses using RV/TLC as a marker of air trapping (Table S1 in Online Supplement), stratification according to BMI (Table S2 in Online Supplement), as well as sensitivity analyses (Table S3 , S4, S5 and S6 in Online Supplement) yielded very similar results. Linear regression goodness of fit tests did not reveal any abnormality.
DISCUSSION
Our study shows that IC/TLC and dyspnoea are associated with 6MWD decline in moderate-to-severe clinically stable COPD patients. However, other variables traditionally considered of clinical relevance in this setting, such as age, BMI or severity of airflow limitation (FEV 1 ), did not influence 6MWD decline in this population once adjusted for selective attrition.
Previous studies
Three previous studies have investigated factors related to 6MWD decline in COPD. 7, 12, 13 Spruit et al. 13 reported in the ECLIPSE cohort that age, BMI and GOLD grades of airflow limitation were significantly related (after adjustment) with exercise capacity deterioration. In the Bergen COPD cohort, Frisk et al. 12 found that airflow limitation severity and self-reported physical activity predicted changes in 6MWD in a multivariate regression model. Finally, Casanova et al., 7 using data from the BODE cohort, found that 6MWD declined significantly in patients with FEV 1 lower than 50% of predicted, although the association was not adjusted for potentially relevant confounders. None of these studies tested the role of pulmonary function tests other than forced spirometry (i.e., lung volumes or CO diffusing capacity), systemic inflammation, cardiac function, skeletal muscle force and/or concomitant treatments, among others.
A novel finding of our study is that IC/TLC predicts exercise capacity decline. Lung hyperinflation is frequently observed in patients with COPD. It has potentially negative 15 pulmonary and cardiovascular consequences 32 and is a powerful predictor of mortality in these patients 17 . We add to this knowledge by showing that COPD patients with lower IC/TLC experience a higher longitudinal decline in 6MWD. This is in agreement with previous experimental research that demonstrated that a low IC/TLC predisposes to critical mechanical constraints on tidal volume expansion as ventilatory requirements increase, which in turn results in reduced exercise capacity. 16, 33 Secondly, we found that exertional dyspnoea, a cardinal symptom of patients with COPD, 30 was also related to the decline in exercise capacity, independently of static hyperinflation. A strong association between dyspnoea and exercise capacity has been reported in previous cross-sectional studies.
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Also some interventions, such as pulmonary rehabilitation, result in an improvement of both parameters. 1 Then, it is plausible that those COPD patients with worse baseline dyspnoea in our study showed a greater decline in exercise capacity.
At variance with previous studies, we did not observe an association between baseline FEV 1 and exercise capacity decline. Some explanations can be conceived to interpret this discrepancy including: 1) Differences in patients' characteristics among studies.
Our COPD patients walked somewhat more at baseline than those from the ECLIPSE and the BODE cohort (mean 369m and 388m respectively) and had lower airflow limitation than participants in the BODE cohort (mean FEV 1 =39% predicted). This fact could have lead to the detection of different determinants of exercise capacity decline.
2) Failure to consider patients lost to follow up in the analysis of previous studies.
Between 16% and 45% of patients were lost to follow up in these previous studies and they were not included in the analysis. Because patients lost to follow up in longitudinal studies usually have poorer health status and lower FEV 1 values (as also observed in our PAC-COPD cohort), not including them in the analysis may lead to biased results (usually called survival bias).
14 Among the several statistical techniques to deal with survival bias, we used multiple imputation. 15 For didactic purposes, we repeated our analysis with a complete case approach ( Figure S4 ), which resulted in an spurious association between FEV 1 and 6MWD decline. Therefore, consideration of patients lost to follow up in longitudinal analyses using appropriate statistical techniques not only prevents missing relevant information, but, most importantly, reduces bias which increases the validity of the estimates. 35 Also, at difference with Spruit et al., 13 BMI did not play a role in the 6MWD annual decline in our study patients. This may be partly due to the lack of variability in BMI in our COPD study group, preventing us to detect possible association or interactions with exercise capacity decline. Also, the lack of association between 6MWD decline and participation in pulmonary rehabilitation is likely explained by the reduced number of patients enrolled in such programmes in our study sample (n=13).
Clinical implications
Timed walking tests, and specially the 6MWD, have been extensively used in the clinical evaluation of patients with COPD, mainly because of their simplicity, reliability and safety. At present, it is recognized that this test adds useful information for the clinical staging of patients (e.g., the BODE index 36 ). Moreover, longitudinal changes in the 6MWD are strong predictors of mortality. [8] [9] [10] It is therefore important to identify factors associated with this decline in exercise capacity in order to better tailor potential therapeutic interventions, such as pulmonary rehabilitation, that can modify this course.
The 2013 ATS/ERS Task Force statement on pulmonary rehabilitation highlights that any individual with chronic respiratory disease could be referred to a pulmonary rehabilitation programme. 1 However, in real life such programmes are not accessible to many COPD patients from around the world due to the cost-constraint situation in many healthcare systems. Our group previously reported that hospital admissions, frequently observed in COPD patients during the course of their disease, may accelerate the decline of exercise capacity in these patients, 25 suggesting that patients admitted to a hospital are potential candidates to benefit the most from pulmonary rehabilitation. Our current analysis extends these previous observations and shows that the assessment of clinically stable COPD patients might help clinicians to predict future changes in exercise capacity. We propose that severe dyspnoea and IC/TLC, because of their association with exercise capacity decline, could be used as indicators to prioritise candidates for pulmonary rehabilitation.
Finally, our results might also help to identify those COPD patients who could benefit most from treatments that enable to increase tidal volume during activities, including some drugs and lung volume reduction strategies, thus reducing exertional dyspnoea and interrupting the vicious cycle of worsening exercise capacity.
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Strengths and limitations
The consideration of static volumes and other relevant clinical and functional variables not covered in previous research is a clear strength of our study. Likewise, the large cohort of COPD patients (all recruited at the same disease evolution stage) with wide spectrum of disease severity is another strength. Finally, we used multiple imputations to account for selective attrition and missing values, as missing data could have introduced bias in our estimates.
14 Some limitations of our study, however, should also be noted and discussed. First, even though the PAC-COPD study had no exclusion criteria in relation to sex, few women were included, so we cannot generalise the results to both sexes. Also, since patients were recruited at their first hospitalisation they may not represent the COPD population at large. Finally, only two evaluations were performed during the study period and the time span between them was relatively short (1.7 y). Descriptive analyses conducted using imputed datasets where existing missing data. Characteristics of study participants at baseline using complete cases and imputed datasets have been previously reported 25 . †: All patients had at least one exacerbation in the previous year, as they were recruited during their first COPD admission. ‡: According to the criteria of the ATS/ERS. Table S1 . Adjusted predictive factors of exercise capacity decline in 342 COPD patients followed up for 1.7 years (linear regression model), using RV/TLC as a marker of air trapping.
Conclusions
- Table S2 . Adjusted predictive factors of exercise capacity decline in 342 COPD patients followed during 1.7 years (linear regression model), according to baseline BMI.
- Table S3 . Adjusted predictive factors of exercise capacity decline in 342 COPD patients followed during 1.7 years (linear regression model), using complete cases and imputed datasets.
- Table S4 . Adjusted predictive factors of exercise capacity decline expressed in absolute values and as percentage with respect to baseline level in 342 COPD patients followed during 1.7 years (linear regression model).
- Table S5 . Adjusted predictive factors of exercise capacity decline in 342 COPD patients followed during 1.7 years (linear regression model), excluding patients enrolled in pulmonary rehabilitation programs. patients followed during 1.7 years (linear regression model), forcing variables previously related to 6MWD decline.
- Figure S1 . Relationship between relevant socio-demographic, life-style and clinical data and the annual change in 6-minute walk distance (6MWD) in 342 COPD patients.
- Figure S2 . Relationship between anxiety and depressive symptoms, lung function parameters, blood gases, muscle force, cardiac function and the annual change in 6-minute walk distance (6MWD) in 342 COPD patients.
- Figure S3 . Relationship between relevant inflammatory markers, bronchial colonisation and respiratory treatments at baseline and the annual change in 6-minute walk distance (6MWD) in 342 COPD patients.
- Figure S4 . Relationship between airflow limitation (FEV 1 ) and the annual change in 6-minute walk distance (6MWD) in 342 COPD patients, using complete case and multiple imputations strategies.
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METHODS-COMPLETE VERSION
Study design and participants
Subjects were recruited during their first hospitalization due to a COPD exacerbation in 
Measurements
Assessments were performed on clinical stability and at least 3 months after discharge.
Exercise capacity was assessed by the 6-minute walk test (6MWT). 4 In the first visit, patients completed two tests with at least a 30-min rest between them, and the longest of both 6-minute walk distances (6MWD) was used for analysis. Only one test was conducted in the second evaluation. The annual rate of change in exercise capacity was defined as the difference between the distance walked at the second evaluation minus that at baseline divided by follow-up time in each subject. Heart rate, oxygen saturation, dyspnoea and fatigue score (Borg scale) 5 were collected before and at the end of each exercise test. Patients also answered a computerized epidemiological questionnaire that included socio-demographic data, life-style information, the modified Medical Research Council (mMRC) scale for the assessment of dyspnoea, 10 and self-reported co-morbid conditions. The Charlson index of comorbidity 11 was calculated accordingly. Physical activity was assessed using the Yale Physical Activity Survey (YPAS) 12 in its Spanish version validated for COPD patients. 13 The validated Spanish-language version 14 of the St George's Respiratory Questionnaire (SGRQ) 15 was used to measure health status.
Anxiety and depression were assessed using the validated Spanish-language version 16 of the Hospital Anxiety and Depression Scale (HAD). 17 Information on concomitant medications use, continuous long-term oxygen therapy, participation in pulmonary rehabilitation programs and exacerbations in the previous year (defined as a worsening of the patient's respiratory symptoms that required a change in medication) 18 were also collected at baseline.
Weight and height were measured and the body mass index (BMI) was calculated and the fat free mass index (FFMI) was obtained by bioimpedance. Data on airway inflammatory markers (interleukin [IL] -1ß, IL-6, IL-8 concentration) and bronchial colonisation were collected and assessed as previously reported. 19 Serum levels of Creactive protein and tumour necrosis factor-α were also determined, as reported elsewhere. 1, 19 C-reactive protein levels greater than 5 mg/L were considered as elevated 20 . Cardiac function was assessed by Doppler echocardiography following standardized methodology and emphysema quantification was assessed by High-Resolution
Computed Tomography (HRCT). 21, 22 Emphysema was defined as sharply delineated low-density areas subdivided into acinar, panlobular or subpleural in both lungs.
Emphysema was expressed as a dichotomous variable (presence or absence) Detection of emphysema in any lobe was considered as the presence of emphysema. 23 A hand dynamometer was used to measure peripheral muscle function. Detailed information about the methods, questionnaires, standardization of the tests, and fieldwork supervision has been previously reported.
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Statistical analysis
Sample size of 342 was fixed by the primary scientific objectives of the PAC-COPD Study. 22 Prior to any analysis we calculated, using the program GRANMO 5.2, 24 that statistical power was 96% using data from the literature on 6MWD, 25,26 assuming a difference of 40 m in 6MWD between two equally sized groups, and accepting an alpha risk of 0.05 in a two-sided contrast.
To account for selective attrition and missing values, we used multiple imputation (20 times) through chained equations, replacing missing values by imputations drawn from the predicted distribution of each variable. 27 By performing these analyses all data from 342 PAC-COPD patients were included. Characteristics of study participants at baseline using complete cases and imputed datasets have been previously reported. using Students' t test or ANOVA, as appropriate depending on the number of categories of the independent variable. Those of them that were significantly related to the outcome were then introduced in a multiple linear regression model to determine the predictors of exercise capacity decline, after adjusting for baseline 6MWD. Variables were kept in the model if they were significantly associated with the outcome and/or they modified (at least 10%) the coefficient for other variables in the model. Goodness of fit was assessed by means of normality of residuals, heteroscedasticity, linearity, collinearity and identification of influential data. Because previous research has identified different determinants of exercise capacity in obese and normal weighted COPD patients, 28 we stratified the models according to BMI. Additional analyses using reserve volume/total lung capacity (RV/TLC) as a marker of air trapping were also implemented. Finally, sensitivity analyses were conducted (i) using complete case analyses, (ii) measuring changes in the 6MWD as percentage with respect to baseline level, (iii) excluding patients enrolled in pulmonary rehabilitation programs, and (iv) forcing into the model variables previously related to 6MWD decline. [29] [30] [31] Analysis was conducted using Stata 12.1 (StataCorp, College Station, TX, USA). A p<0.05 was considered significant. Definition of abbreviation: 95% CI = 95% confidence interval; mMRC = Modified Medical Research Council dyspnoea scale; RV/TLC= residual volume/total lung capacity; IC/TLC= inspiratory capacity/total lung capacity; SGRQ= Saint George's respiratory questionnaire 6MWD= 6-minute walk distance; 6MWT= 6-minute walk test. *Adjusted mean value based on the linear regression equation corresponding to the mean change in 6-minutes walking distance in a subject with mMRC<2 and mean RV/TLC ratio (or mean IC/TLC), SGRQ, C-reactive protein, Borg dyspnoea at the end of 6MWT and mean baseline 6-minute walk distance. Negative values represent decline. †Coefficients are expressed as changing meters of the six-minute walk distance per (i) each unit of the continuous covariates, or (ii) a change with respect to reference category in categorical covariates. Data are presented as mean and 95% coefficient intervals. Definition of abbreviations: FEV 1 = forced espiratory volume in 1 second; 6MWD= 6-minute walk distance.
